Emily Kaiser Maharjan, Assistant Managing Editor

Adam Ramsey, OD, shares key takeaways from his presentation on diversity, equity, and inclusion in you optometry practice, which he presented during EyeCon 2022.

The preservative-free, multi-dose contact lens rehydrating drops are expected to hit the market in early 2023.

The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.

Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.

The #GlassesOn campaign promotes the benefits of eyewear for kids and invites support for the non-profit through Giving Tuesday on November 29th.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.